Grifols (GIKLY) Liabilities and Shareholders Equity (2009 - 2025)
Grifols (GIKLY) posted Liabilities and Shareholders Equity of $22.9 billion for Q4 2025, little changed quarter-over-quarter from $22.9 billion in Q4 2024, and little changed year-on-year from $22.9 billion in Q4 2024.
Grifols (GIKLY) Liabilities and Shareholders Equity (2009 - 2025) Analysis & Trends
Grifols (GIKLY) has reported Liabilities and Shareholders Equity for 16 consecutive years, with $22.9 billion the latest figure, recorded in Q4 2025.
- Liabilities and Shareholders Equity for Q4 2025 came in at $22.9 billion, changed 0.32% year-over-year; the trailing twelve-month figure through Dec 2025 was $90.1 billion (up 1.06% YoY), and the FY2025 annual result was $22.9 billion, up 28227.93% from the prior year.
- Liabilities and Shareholders Equity was $22.9 billion for Q4 2025 at Grifols, roughly flat from $22.9 billion in the prior quarter.
- Over five years, Liabilities and Shareholders Equity peaked at $22.9 billion in Q4 2025 and troughed at $21.7 billion in Q4 2022.
- Average Liabilities and Shareholders Equity over 5 years is $22.4 billion, with a median of $22.6 billion recorded in 2023.
- Year-over-year, Liabilities and Shareholders Equity gained 20.82% in 2021 and declined 1.56% in 2022.
- Over 5 years, Liabilities and Shareholders Equity stood at $22.0 billion in 2021, then slipped by 1.56% to $21.7 billion in 2022, then advanced by 4.28% to $22.6 billion in 2023, then increased by 1.27% to $22.9 billion in 2024, then increased by 0.32% to $22.9 billion in 2025.
- Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $22.9 billion in Q4 2025, $22.9 billion in Q4 2024, and $22.6 billion in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 116.58 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 200.89 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 136.46 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 114.02 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 128.69 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 92.50 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 56.28 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 208.00 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Grifols | - | - | - | 22.95 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 22.95 Bn |
| Dec 31, 2024 | 22.87 Bn |
| Dec 31, 2023 | 22.59 Bn |
| Dec 31, 2022 | 21.66 Bn |
| Dec 31, 2021 | 22.00 Bn |
| Dec 31, 2020 | 18.21 Bn |
| Dec 31, 2019 | 17.20 Bn |
| Dec 31, 2018 | 14.24 Bn |
| Dec 31, 2017 | 12.86 Bn |
| Dec 31, 2016 | 10.94 Bn |
| Dec 31, 2015 | 10.52 Bn |
| Dec 31, 2014 | 10.56 Bn |
| Dec 31, 2013 | 7.95 Bn |
| Sep 30, 2013 | 7.57 Bn |
| Jun 30, 2013 | 7.63 Bn |
| Mar 31, 2013 | 7.64 Bn |
| Dec 31, 2012 | 7.30 Bn |
| Sep 30, 2012 | 7.30 Bn |
| Jun 30, 2012 | 7.60 Bn |
| Mar 31, 2012 | 7.27 Bn |